485 ROUTE 1 SOUTH, ISELIN, NJ
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Other Events
CFO Transition - Lawrence A. Kenyon Departs, Kevin Lundquist Appointed
Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Outlook Therapeutics, Inc. Announces Public Offering of 55.56 Million Shares
Significant losses and negative cash flows expected to continue.
Other Events, Press Release
Stock Options Granted to CEO Robert C. Jahr and CFO Lawrence A. Kenyon
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
FY 2025
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report